Delving into the Latest Updates on Quinine Sulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Qualaquin, Quinine capsules, Quinine hydrogen sulfate

+ [9]

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Malaria

Inactive Indication

Malaria, FalciparumRenal Insufficiency

Originator Organization

Sun Pharmaceutical Industries Ltd.

Active Organization

Arrotex Pharmaceuticals Pty Ltd.StartupGrand Pharmaceutical Group

Inactive Organization

Mutual Pharmaceutical Co., Inc.

Sun Pharmaceutical Industries, Inc.

Drug Highest PhaseApproved

First Approval Date

Australia (14 Feb 2005),

Malaria

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC20H24N2O2

InChIKeyLOUPRKONTZGTKE-WZBLMQSHSA-N

CAS Registry130-95-0

View All Structures (2)

This is a multicenter, randomized, open-label, controlled trial to evaluate the effectiveness and safety of Quinine Sulfate as an add-on therapy in hospitalized adults with COVID-19.
The study is a multi-center trial that will be conducted in up to approximately 2 sites nationally. New sites may be added as needed after appropriate assessment. Interim monitoring will be conducted to evaluate the arms and for safety and effectiveness. Any changes would be accompanied by an updated sample size.
Subjects will be assessed while hospitalized. All subjects will undergo a series of laboratory tests (CBC, SGOT, SGPT, Ureum, Creatinine, EKG, and PCR), clinical examination (clinical assessment, vital signs, accompanying drugs, and other medical conditions) and safety assessment (serious adverse events/ SAE)
Randomization will be performed 1:1 for each arm. Arm 1 = Standard of Care (SoC) alone, arm 2 = SoC + Quinine Sulfate

Start Date26 Apr 2021

Sponsor / Collaborator

Universitas Padjadjaran

[+1]

NCT02598713

/ Unknown statusPhase 1IIT

Validation of Markers for Aspiration for Endotracheal Tube Cuff Leak

The goal of this interventional study is to test Quinine as marker of aspiration (endotracheal tube [ETT] cuff leakage) in mechanically ventilated, critically ill patients.

Start Date01 Dec 2015

Sponsor / Collaborator

The General Hospital Corp.

NCT02630472

/ TerminatedPhase 1/2IIT

Efficacy and Safety of Adjuvant Topical Irrigation in the Treatment of Acute Exacerbation of Chronic Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)

The purpose of the study is to evaluate the physiologic response of quinine-saline irrigations for acute exacerbation of uncomplicated chronic rhinosinusitis following endoscopic sinus surgery. Subjects who have previously had functional endoscopic sinus surgery with acute exacerbation of chronic rhinosinusitis will be randomized to either a quinine-saline or saline-placebo arm. The investigators will measure baseline and follow-up clinical and quality-of-life outcomes for both arms, and then compare the groups at the end of the study period. The investigators' hypothesis is that the participants in the quinine sulfate arm will perform better on all measures as compared to the control arm.

Start Date01 Oct 2015

Sponsor / Collaborator

University of Pennsylvania

100 Clinical Results associated with Quinine Sulfate

Login to view more data

100 Translational Medicine associated with Quinine Sulfate

Login to view more data

100 Patents (Medical) associated with Quinine Sulfate

Login to view more data

11,920

Literatures (Medical) associated with Quinine Sulfate

01 Apr 2025·Journal of Photochemistry and Photobiology A: Chemistry

Acoustic cavitation assisted synthesis of PCDs@PVA composite film for UV shielding, intelligent pH detection, information encryption and food packing applications

Author: Sandeep, D. H. ; Sahoo, Srikant ; Wu, Sheng Yun ; Nagabhushana, H. ; Sharma, S. C. ; Sridhar, C. ; Krushna, B. R. Radha ; Manjunatha, K. ; Arulmozhi, A. ; Kumar, V. R. Hemanth ; Rajkumar, Ambrose

Excessive exposure to UV and high-energy blue light (HEBL) can severely damage the skin and eyes.Therefore, it is essential to protect our bodies from UV and HEBL radiation.We created PEG-derived carbon dots (PCDs) using the acoustic cavitation approach in order to completely block UV and HEBL.The influence of different exptl. parameters such as sonication time, amplitude, and temperature on the PCDs is examinedThe optimized PCDs are found to have an average diameter ranging from 5 to 9 nm, contingent upon the preparation circumstances, and to have a quantum yield (QY) of 14-16%.The PCDs vivid color and simultaneous UV and HEBL absorption properties allowed the PVA film containing 0.120 wt% of PCDs to demonstrate outstanding blocking efficiency, with 99.9% blocking in HEBL and 100% blocking in UV-C, UV-B, and UV-A.The photoluminescence (PL) behavior of PCDs is greatly reduced by Fe⁺³ ions because of strong excited state electron transfer.This fluorescent 'turn-off' behavior towards Fe⁺³ is highly selective and sensitive with a limit of detection (LoD) of 0.366μM.Paper-based sensors incorporating PCDs are developed for the rapid and accurate detection of Fe Fe⁺³ in surface water, wastewater treatment plant effluent, and tap water, leveraging their excellent sensitivity and selectivity towards Fe⁺³ .The characteristics of ink-free patterned substrates are displayed by PCDs scattered across a PVA matrix, which makes them useful for the non-destructive acquisition and recognition of latent fingerprints (LFPs).A flexible, transparent film is produced when a LFP is exposed to a PCDs@PVA solutionIn this film, a steady luminous fingerprint with specific ridge characteristics that aid in personal recognition is seen.This method shows promise for lifting and identifying long-exposed LFPs from various surfaces without causing damage.It is believed that the interfacial segregation of PCDs inside the PVA matrix during the film production process serves as a mechanism for LFP collection and visualization.The YOLOv8x program, which utilizes deep convolutional neural networks, is employed to analyze the discernible features present in fingerprints (FPs).Notably, their exceptional flexibility, foldability, and sustainability create new opportunities for use in the anti-counterfeiting (AC) field.Because of its remarkable fluorescence stability, it may be a viable substitute for conventional fluorescent inks.Fresh green apples are observed over time after being coated with 0.120 wt% PCDs@PVA and PVA.Virtual assessments indicated that the 0.120 wt% PCDs@PVA film coating significantly reduced weight and moisture loss, effectively inhibiting fungal growth and spoilage for over 25 days at room temperature (RT).Overall, the results clearly show that the PCDs@PVA film is easy to make, flexible, safe for the environment, and resistant to photodegradationHemolysis, and blood clotting exhibited favorable biocompatibility and nontoxicity.

01 Mar 2025·Food Chemistry

Bifunctional nanobody facilitates a colorimetric and fluorescent dual-mode immunoassay of Staphylococcal enterotoxin A

Article

Author: Zhou, Ting ; Zhao, Qin ; Tian, Yudong ; Yu, Ying ; Zheng, Wanxiang ; Li, Min ; Dai, Yanna ; Li, Yuhuan ; Pan, Hu ; Liu, Di ; Zhang, Yao ; Zhang, Min ; Dawa, Zhuoma ; Wang, Xin

Immunoassay is a diagnostic tool based on the specific binding of antibodies and antigens with widespread applications. Nonetheless, several research obstacles, like poor specific antibodies, the poisonous reagents and unstable results, still remain challenges. Herein, we innovatively reported a colorimetric and fluorescent dual-mode immunoassay based on the bifunctional nanobody for SEA detection. Benefiting from the advantages of nanobodies, the bifunctional protein with both recognition and catalysis was built to identify and catalyze with efficiency to generate the first colorimetric signal. Meanwhile, the introduction of quinine as the natural source of the second fluorescent signal greatly improved the stability and safety of detection. In addition, the proposed method was successfully applied to detecting SEA in food samples with high accuracy and stability. This study integrated the bifunctional nanobody with eco-friendly fluorescent product to provide a specific and green platform for the detection of foodborne toxins.

17 Feb 2025·Chemistry – A European Journal

Reusable Ni‐Immobilized MOF Catalyst for Dehydrogenation of N‐Heterocycles Under Milder Conditions

Article

Author: Saifi, Shadab ; Banerjee, Debasis ; Sk, Motahar ; Aijaz, Arshad ; Ghosh, Adrija ; Bera, Sourajit

AbstractHerein, we have demonstrated the design and synthesis of a novel Ni‐immobilized MOF as heterogeneous catalyst for the dehydrogenation of N‐heterocycles. A series of five and six‐membered N‐heteroarenes bearing one or more heteroatoms were synthesized in up to 98 % yield (>33 examples). Late stage functionalization to the synthesis of β‐glucuronides inhibitor, antimalarial drug quinine, and the nonsteroidal anti‐inflammatory drug (NSAID) indomethacin were obtained under milder reactions conditions. A series of mechanistic studies revealed the detection of H2 and H2O2 during the progress of the reactions and suggested the involvement of enamine‐imine intermediate species for sequential dehydrogenation. Detailed characterization of the fresh catalyst and reused catalyst were performed using SEM, TEM, BET, PXRD, and EDX elemental mappings. The catalyst could be recycled up to four‐times without much loss in catalytic activities. In‐situ formed defects, pore size enlargement and additional Lewis acid sites within catalyst nanocrystals assisted in attaining high activity and selectivity to N‐heteroarenes.

100 Deals associated with Quinine Sulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02262	Quinine Sulfate	P01BC01	DB00468

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Malaria	China	Grand Pharmaceutical Group	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Insufficiency	Phase 2	United States	Mutual Pharmaceutical Co., Inc.	01 Nov 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02630472 (QSIND, CTgov)	Phase 1/2	Rhinitis \| Chronic sinusitis	10	Quinine Sulfate (Quinine Sulfate)	kpfatmmoul(ukrqfpekjv) = jjlfluosvw yyddcqfsos (caqripkhtv, qhxerpuasf - chxwruniso) View more	-	13 Mar 2019
				Placebo (Placebo)	kpfatmmoul(ukrqfpekjv) = secfrtabqy yyddcqfsos (caqripkhtv, hcbpprhvmv - zemyarnwqe) View more
NCT00726414 (CTgov)	Phase 1	-	22	Quinine Sulfate (Quinine Sulfate Under Fasted Conditions)	necnbnmxnj(ldjzraaduf) = broodpther bbgzepgieq (ldxdqfeydk, wdhbrnhbnr - niggkbgmon) View more	-	03 Feb 2010
				Quinine Sulfate (Quinine Sulfate Under Fed Conditions)	necnbnmxnj(ldjzraaduf) = pwgbrkvvcd bbgzepgieq (ldxdqfeydk, odbqtctwys - yugkpeiixo) View more
NCT00727272 (CTgov)	Phase 1	-	27	Quinine Sulfate (Treatment A - Quinine Sulfate 324 mg Caps, Fasting Conditions)	(dtmsvngubw) = kbmtdlqler mvrqbmbrrf (jtluhtwxhx, uritpszrgd - kfoipjzelp) View more	-	30 Dec 2009
				Quinine Sulfate (Treatment A, Dose Adjusted to 300 mg)	(dtmsvngubw) = ejtwdssdiy mvrqbmbrrf (jtluhtwxhx, rpsvygqhmg - gkebperxtn) View more
NCT00726895 (CTgov)	Phase 1	-	24	Quinine Sulfate (Treatment A - Quinine Sulfate Capsules (1 x 324 mg Dose))	(bthzrpwapk) = gnhwcttzof bzosmyudqb (mkwqbttvbu, cunfwmyfgd - obelubpnko) View more	-	30 Dec 2009
				Quinine Sulfate (Treatment A, Dose Adjusted to 2 x 324 mg)	(bthzrpwapk) = khmouyqfsu bzosmyudqb (mkwqbttvbu, nilwnahorx - qlprcrdpmu) View more
NCT00785486 (CTgov)	Phase 1	-	24	Midazolam Alone	qulqakftww(gvovpscdvd) = soltfxuawm cehsskpsoo (ujmqzlisoi, yhqttjghvf - llyipjfrje) View more	-	08 Jul 2009